Clinical trials: Antibody
Renal Cell Carcinoma
Phase I Biomarker Study (BMS-936558)
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
- Trial name
- NCT01358721
- Testing
- BMS-936558 (Anti-PD-1)
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers…
- Trial name
- NCT02908906
- Testing
- JNJ-63723283
- Where
- 20 sites in United States, Moldova and 5 more
- Volunteers
- 234 people
- Sponsor
- Janssen Research & Development, LLC
Coronavirus Disease 2019 COVID-19
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and…
- Trial name
- NCT04341116
- Testing
- TJ003234
- Where
- 14 sites in United States
- Volunteers
- 149 people
- Sponsor
- I-Mab Biopharma US Limited
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with…
- Conditions
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Trial name
- NCT02912949
- Testing
- zenocutuzumab (MCLA-128)
- Where
- 64 sites in United States, Austria and 16 more
- Volunteers
- 250 people
- Sponsor
- Partner Therapeutics, Inc.
HBV
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
The objective of this protocol is the collection and testing of clinical samples to determine the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer.
- Trial name
- NCT04904835
- Testing
- Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- Where
- 5 sites in France
- Volunteers
- 21,210 people
- Sponsor
- Beckman Coulter, Inc.
Dermatitis, Atopic
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.
- Trial name
- NCT06324812
- Testing
- Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Systemic Lupus Erythematosus
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
- Trial name
- PLUTO (NCT01649765)
- Testing
- Belimumab 10 mg/kg
- Where
- 32 sites in United States, Argentina and 8 more
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Liver Transplantation
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
- Trial name
- NCT06019507
- Testing
- TCD601, Cyclophosphamide, TAC
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- ITB-Med LLC
IgAN, LN
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3…
- Conditions
- IgAN, LN, MN, C3G
- Trial name
- NCT02682407
- Testing
- OMS721 (narsoplimab)
- Where
- 12 sites in United States, Hong Kong
- Volunteers
- 31 people
- Sponsor
- Omeros Corporation
CD123+ Acute Myeloid Leukemia
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid…
- Trial name
- NCT07809906
- Testing
- ORM-1153
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Orum Therapeutics USA, Inc.
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Hepatocellular Carcinoma
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
An open-label multi-center phase II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 alone or in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT04728321
- Testing
- AK104 lenvatinib, AK104
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Akeso
Solid Tumor
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with…
- Trial name
- NCT03099109
- Testing
- LY3321367, LY3300054
- Where
- 15 sites in United States, Japan and 2 more
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
End-Stage Kidney Disease (ESKD)
Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard…
- Trial name
- NCT07759167
- Testing
- REGN9933, REGN7508, REGN9533
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Urothelial Carcinoma
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.
- Trial name
- IMvigor130 (NCT02807636)
- Testing
- Atezolizumab, Carboplatin, Gemcitabine
- Where
- 204 sites in United States, Australia and 33 more
- Volunteers
- 1,213 people
- Sponsor
- Hoffmann-La Roche
Early Rheumatoid Arthritis
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy…
- Trial name
- PREMIER (NCT00195663)
- Testing
- Adalimumab, Methotrexate
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 799 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
COVID-19
SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
To evaluate the safety, tolerance, local drug content and neutralization activity in nasal cavity, systemic exposure level and immunogenicity of novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray.
- Trial name
- NCT06048393
- Testing
- SA55 nasal spray
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.